12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eltoprazine: Phase II data

A double-blind, Swedish Phase II trial in 22 patients with PD showed that single doses of 5 and 7.5 mg oral eltoprazine each met the primary endpoint of reducing PD-LID without adversely affecting the efficacy of levodopa vs. placebo (p=0.0007 and p=0.0467, respectively). Eltoprazine...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >